Neuropsychobiology
February 5, 2026
Lavanya Seth, Jitendriya Biswal, Surjeet Sahoo et al.
Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressant therapy. Electroconvulsive therapy (ECT) remains a cornerstone treatment for refractory depression, while ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a rapid-acting antidepressant with potential benefits in...
Neuropsychobiology
August 10, 2023
Effectiveness and Changes in Brain Functions by an Occupational Therapy Program Incorporating Mindfulness in Outpatients with Anxiety and Depression: A Randomized Controlled Trial.
Neuropsychobiology
2013
Jan A. Moynihan, Benjamin P. Chapman, Rafael Klorman et al.
213 citations
BACKGROUND/AIMS: Mindfulness-based stress reduction (MBSR) has enhanced cognition, positive emotion, and immunity in younger and middle-aged samples; its benefits are less well known for older persons. Here we report on a randomized controlled trial of MBSR for older adults and its effects on executive function, left frontal asymmetry of the EEG alpha band, and antibody response. METHODS: Older...
Neuropsychobiology
2012
Franziska Hürlimann, Stephan Kupferschmid, Andor E Simon
We present a case series of 6 patients who developed persistent depersonalization disorder in adolescence after consuming cannabis. In 2 of these cases, the illness course was severely disabling. Within the growing body of literature that investigates the effects of cannabis use on mental health, the association between cannabis and depersonalization disorder is widely neglected. We review the...
Neuropsychobiology
2011
Tomáš Páleníček, Michaela Fujáková, Martin Brunovský et al.
85 citations
AIMS: This study was designed to evaluate the changes in EEG power spectra and EEG coherence in a ketamine model of psychosis in rats. Analyses of behavioral measurements--locomotion and sensorimotor gating--and the pharmacokinetics of ketamine and norketamine were also conducted. METHODS: Ketamine and norketamine levels in rat sera and brains were analyzed by gas chromatography-mass...
Neuropsychobiology
October 20, 2010
Andrew Scholey, Lauren Owen, J. R. Gates et al.
46 citations
<i>Aims:</i> Our group has conducted several Internet investigations into the biobehavioural effects of self-reported recreational use of MDMA (3,4-methylenedioxymethamphetamine or Ecstasy) and other psychosocial drugs. Here we report a new study examining the relationship between self-reported Ecstasy use and traces of MDMA found in hair samples. <i>Methods:</i> In a laboratory setting, 49...
Neuropsychobiology
2009
Susan Schenk
71 citations
The prevalence of 3,4-methylenedioxymethamphetamine (MDMA) use has increased globally and the pattern of consumption has changed considerably. Previously, a subculture of MDMA users was fairly restricted to the dance club scene. More recently, use has spread outside of this subculture and now many users consume MDMA frequently and in large amounts and some meet criteria for drug abuse and/or...
Neuropsychobiology
2009
A.c. Parrott
67 citations
Aims: 3,4-Methylenedioxymethamphetamine (MDMA) can affect both neurotransmitter and neurohormonal activity. This review will debate the role of the metabolic activation hormone cortisol for the psychobiological effects of ecstasy/MDMA. Methods: The empirical literature on cortisol release following acute MDMA administration and cortisol functioning in drug-free recreational ecstasy/MDMA users...
Neuropsychobiology
2009
Philip N. Murphy, Michelle Wareing, John E. Fisk et al.
49 citations
<i>Aims:</i> This review examined studies of executive functioning in abstinent ecstasy (3,4-methylenedioxymethamphetamine, MDMA) users on tasks which had been empirically mapped onto updating, shifting, inhibition and accessing long-term memory executive processes. Studies of some aspects of visuospatial memory performance were also included because of the investment of executive resources in...
Neuropsychobiology
2009
Elena Puerta, Isabel Hervias, Norberto Aguirre
Administration of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to various experimental animals has been shown to induce a selective damage to serotonergic axon terminals. While a great consensus appears to exist regarding the causative role of reactive oxygen species (ROS) in the mechanisms underlying MDMA toxicity, the source of free radicals is still a matter of debate. While some...
Neuropsychobiology
2009
Wael M.Y. Mohamed, Sami Ben Hamida, Anne Pereira de Vasconcelos et al.
Methylenedioxymethamphetamine (MDMA, ecstasy) is a widely used recreational drug, often associated with dance parties. Users self-report euphoria, a sense of well-being and increased feelings of affiliation. In experimental animals, MDMA produces an acute, rapid release of serotonin and, to a lesser extent, dopamine and norepinephrine in the brain. It can also produce a dose-dependent,...
Neuropsychobiology
2009
Raimondo Bruno, Allison J Matthews, Libby Topp et al.
Although use of 'ecstasy' (drugs sold as containing 3,4-methylenedioxymethamphetamine) is prevalent, it is typically infrequent, and treatment presentations involving ecstasy as a principal problem drug are relatively rare. Human case reports and animal literature suggest dependence potential, although there may be some unique aspects to this syndrome for ecstasy in comparison to other...
Neuropsychobiology
2009
Clare Dickson, Raimondo Bruno, John Brown
A growing body of evidence suggests that regular 'ecstasy' (3,4-methylenedioxymethamphetamine) use causes lasting changes to central serotonergic functioning in humans, including in the occipital lobe. Serotonin may play a role in visual orientation processing, mediated in the occipital lobe, via lateral inhibition. The tilt aftereffect is an illusion apparent following adaptation to stimuli...
Neuropsychobiology
2009
P.S. Van Nieuwenhuijzen, K.M. Li, G.E. Hunt et al.
Users of the popular party drug 3,4-methylenedioxymethamphetamine (MDMA) sometimes report combining MDMA with γ-hydroxybutyrate (GHB) to enhance the pleasurable effects of both drugs. However, very few studies have examined the influences of this drug combination. The present study investigated the development of locomotor sensitization in laboratory rats given 7 once-weekly exposures to either...
Neuropsychobiology
February 20, 2008
P. Etévenon, S. Guillou
11 citations
A night of sleep has been recorded under the conditions of a sleep laboratory. The subject was a woman of 55 years, well-trained in dream recall. The subject was awakened three times at the end of sleep cycles. EEG was monitored for 7 h with a 16-channel polygraph (REEGA 16, Alvar) connected to two systems of EEG cartography: minicomputers (HP Fourier Analyser 5451 C and HP 1000) and a...
Neuropsychobiology
February 14, 2008
Jean-Michel Gaillard, Marc Phelippeau
The purpose of this study was to investigate the effect of flunitrazepam, a benzodiazepine with strong hypnotic properties, on dream content. Eight normal subjects were studied in laboratory by the awakening technique, and the dream contents were rated by two judges according to nine scaled dimensions: unreality, participation of the dreamer, pleasantness, unpleasantness, verbal aggressivity,...
Neuropsychobiology
2008
A. C. Parrott, Jing Zhan Lock, A.c. Conner et al.
77 citations
<i>Background/Aims:</i> The present study is the first to prospectively compare a group of recreational Ecstasy users when dance clubbing on 3,4-methylenedioxymethamphetamine (MDMA) and when clubbing during abstinence from Ecstasy/MDMA. <i>Methods:</i> Twelve normal healthy volunteers (mean age = 23.2 years) were assessed at a Saturday night dance club under self-administered MDMA. On the other...
Neuropsychobiology
2008
Paolo Fusar‐poli, Stefan Borgwardt
7 citations
to experience 'an extremely stimulated imagination' caused by an accidental ingestion of LSD.Three days later, on April 19, 1943, he decided to verify his results by intentionally ingesting LSD.This day has become known as 'Bicycle Day' as Hofmann experienced an incredible bicycle ride on his way home from the lab.LSD was initially hailed as a wonder drug for use in psychoanalysis, particularly...
Neuropsychobiology
2005
Torsten Passie, Matthias Karst, Birgitt Wiese et al.
35 citations
This is the first neuropsychological study using the S-enantiomer of the noncompetitive N-methyl-D-aspartate antagonist ketamine. In 2 randomized placebo-controlled trials we studied effects of two different doses of (S)-ketamine (low dose/high dose) on neuropsychological functions and psychopathology in 12 healthy male volunteers. Impairment was measured via standardized neuropsychological...
Neuropsychobiology
2004
A. C. Parrott
152 citations
MDMA (3,4-methylenedioxymethamphetamine) or ‘ecstasy’ is a ring-substituted amphetamine derivative, which is widely used as a recreational drug, most particularly at dances and raves. Around 80–95% of dancers/ravers report using ecstasy/MDMA, compared to 5–15% of young people in general. This paper will consider the possible contribution of stimulatory environmental conditions to the...
Neuropsychobiology
2004
T. Murata, T. Takahashi, Toshihiko Hamada et al.
145 citations
Meditation is a specific consciousness state in which deep relaxation and increased internalized attention coexist. There have been various neurophysiological studies on meditation. However, the personal predispositions/traits that characterize the properties of meditation have not been adequately studied. We analyzed changes in neurophysiological parameters [EEG coherence and autonomic nervous...
Neuropsychobiology
2004
Jordi Riba, P. Anderer, F Jané et al.
131 citations
<i>Ayahuasca,</i> a South American psychotropic plant tea obtained from <i>Banisteriopsis caapi</i> and <i>Psychotria viridis</i>, combines monoamine oxidase-inhibiting β-carboline alkaloids with N,N-dimethyltryptamine (DMT), a psychedelic agent showing 5-HT<sub>2A</sub> agonist activity. In a clinical research setting, <i>ayahuasca</i> has demonstrated a combined stimulatory and psychedelic...
Neuropsychobiology
2004
Nikolas Coupland, Tai-Jui Chen, Terence O'Donnell et al.
1 citation
event-related potentials 1, 167, 182 -evoked potentials 128, 288, 292 Autistic disorder 157 Averaged diffusion coefficient 119 'Ayahuasca' 89 Bipolar disorder 206, 239 ß-Carboline alkaloids/N,N-dimethyltryptamine ('ayahuasca') 89 Catechol-O-methyltransferase gene 153 Caudate nucleus 296 Cerebellar peduncle 119
Neuropsychobiology
2002
Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Stefanie Maier et al.
69 citations
Hallucinogenic drug-induced states are considered as models for acute schizophrenic disorders (experimental psychoses). In a double-blind study with healthy volunteers we investigated the influence of the serotonergic hallucinogen psilocybin, the ecstasy-like drug 3,4-methylenedioxyethylamphetamine (MDE), the stimulant d- methamphetamine and placebo on covert orienting of spatial attention (n =...
Neuropsychobiology
2000
George A. Ricaurte, Jie Yuan, Una D. Mccann
291 citations
The popular recreational drug, (±)3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) is a potent and selective brain serotonin (5-HT) neurotoxin in animals. MDMA-induced 5-HT neurotoxicity can be demonstrated using a variety of neurochemical, neuroanatomical and, more recently, functional measures of 5-HT neurons. Although the neurotoxic effects of MDMA in animals are widely accepted, the...